ATE512961T1 - Amorphes nebivolol hydrochlorid und seine herstellung - Google Patents

Amorphes nebivolol hydrochlorid und seine herstellung

Info

Publication number
ATE512961T1
ATE512961T1 AT06021645T AT06021645T ATE512961T1 AT E512961 T1 ATE512961 T1 AT E512961T1 AT 06021645 T AT06021645 T AT 06021645T AT 06021645 T AT06021645 T AT 06021645T AT E512961 T1 ATE512961 T1 AT E512961T1
Authority
AT
Austria
Prior art keywords
nebivolol
present
amorphic
production
nebivolol hydrochloride
Prior art date
Application number
AT06021645T
Other languages
English (en)
Inventor
Rakesh Sheth
S V Attanti
Hasmukh M Patel
Vinodkumar Gupta
Sunil S Nadkarni
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35653988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE512961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE512961T1 publication Critical patent/ATE512961T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06021645T 2004-07-30 2005-08-01 Amorphes nebivolol hydrochlorid und seine herstellung ATE512961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN811MU2004 2004-07-30

Publications (1)

Publication Number Publication Date
ATE512961T1 true ATE512961T1 (de) 2011-07-15

Family

ID=35653988

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06021645T ATE512961T1 (de) 2004-07-30 2005-08-01 Amorphes nebivolol hydrochlorid und seine herstellung
AT05815690T ATE397605T1 (de) 2004-07-30 2005-08-01 Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05815690T ATE397605T1 (de) 2004-07-30 2005-08-01 Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol

Country Status (16)

Country Link
US (2) US8604222B2 (de)
EP (2) EP1737847B1 (de)
JP (3) JP5757005B2 (de)
KR (1) KR100896266B1 (de)
CN (2) CN101006081B (de)
AT (2) ATE512961T1 (de)
AU (1) AU2005278782B2 (de)
BR (1) BRPI0513672A (de)
DE (1) DE602005007339D1 (de)
ES (1) ES2307219T3 (de)
HR (1) HRP20080297T3 (de)
MX (1) MX2007000911A (de)
PL (1) PL1737847T3 (de)
RU (1) RU2378272C2 (de)
WO (1) WO2006025070A2 (de)
ZA (1) ZA200700765B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513672A (pt) * 2004-07-30 2008-05-13 Torrent Pharmaceuticals Limita processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
EP1839658A1 (de) * 2006-03-30 2007-10-03 Hexal A/S Pharmazeutische Zusammensetzungen enthaltend mikronisiertes Nebivolol
DE502007003278D1 (de) * 2006-08-04 2010-05-12 Alfred E Tiefenbacher Gmbh & C Pharmazeutische Zusammensetzung enthaltend Nebivolol
ITMI20061889A1 (it) * 2006-10-03 2008-04-04 Zambon Spa Processo di preparazione di nebivololo
PL2099790T3 (pl) 2006-11-27 2010-12-31 Zach System Spa Sposób wytwarzania nebiwololu
WO2008089549A1 (en) 2007-01-22 2008-07-31 Genpharm Ulc Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
KR101478855B1 (ko) * 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
EP2163551B1 (de) * 2008-09-08 2011-11-16 Cadila Pharmaceuticals Ltd. Verbesserter Herstellungsprozess für Nebivolol-Hydrocholorid
IT1392067B1 (it) * 2008-10-31 2012-02-09 Zach System Spa Processo di preparazione di nebivololo
WO2010089764A2 (en) * 2009-01-05 2010-08-12 Msn Laboratories Limited Improved process for the preparation of nebivolol hydrochloride
IT1395354B1 (it) 2009-07-23 2012-09-14 Zach System Spa Processo di preparazione di nebivololo
DE102010005953A1 (de) 2010-01-27 2011-07-28 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Nebivolol
US8785664B2 (en) 2010-02-11 2014-07-22 Menarini International Operations Luxembourg S.A. Process for the preparation of nebivolol
IT1397962B1 (it) 2010-02-11 2013-02-04 Menarini Int Operations Lu Sa Processo per la preparazione del nebivololo.
KR20110130872A (ko) * 2010-05-28 2011-12-06 현대약품 주식회사 결정형 염산 네비볼롤을 포함하는 약학 조성물 및 제조방법
US9456997B2 (en) 2010-08-26 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure
IT1402974B1 (it) * 2010-11-30 2013-09-27 Menarini Int Operations Lu Sa Processo per la preparazione del nebivololo.
WO2014031161A1 (en) * 2012-08-22 2014-02-27 Forest Laboratories Holdings Limited Chemical compositions
ES2700973T3 (es) 2014-02-14 2019-02-20 Corden Pharma Int Gmbh Proceso sin base para la preparación de compuestos intermedios de cetona que se pueden usar para fabricar nebivolol
EP2907810A1 (de) 2014-02-14 2015-08-19 Corden Pharma International GmbH Neues Verfahren zur Herstellung von hochreinem Nebivolol-Hydrochlorid
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
JP6154417B2 (ja) * 2015-03-20 2017-06-28 株式会社三共 遊技機
WO2016185492A1 (en) * 2015-05-19 2016-11-24 Ipca Laboratories Limited Process for preparation of nebivolol and it's salts
KR102203229B1 (ko) * 2016-01-08 2021-01-14 에리슨제약(주) 용출률이 개선된 네비보롤을 포함하는 약학적 조성물
WO2017119629A1 (ko) * 2016-01-08 2017-07-13 에리슨제약(주) 용출률이 개선된 네비보롤을 포함하는 약학적 조성물
EP3768378B1 (de) 2018-03-22 2025-08-06 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate
US12576026B2 (en) 2020-07-08 2026-03-17 Extrovis Ag Formulations of nebivolol

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7908031A (nl) 1979-11-01 1981-06-01 Acf Chemiefarma Nv Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen.
DE3033919A1 (de) 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3133156A1 (de) * 1981-08-21 1983-03-10 Herberts Gmbh, 5600 Wuppertal Verfahren zum markieren von verkehrsflaechen und vorrichtung hierfuer
CA1337429C (en) * 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3419131A1 (de) 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
US4681765A (en) * 1984-09-13 1987-07-21 American Home Products Corporation Rapid releasing triamterene containing gelatin capsule dosage forms for once daily antihypertensive use
US4904477A (en) * 1987-07-08 1990-02-27 American Home Products Corporation Spray dried ibuprofen compositions
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
ZA93436B (en) 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
TW355683B (en) 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
CA2190511A1 (en) 1994-05-16 1995-11-23 J. Peter Klein Asymmetric synthesis of chiral secondary alcohols
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
PT801564E (pt) 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico
AU2259197A (en) * 1996-02-09 1997-08-28 Surface Solutions Laboratories, Inc. Water-based hydrophilic coating compositions and articles prepared therefrom
BR9709556A (pt) * 1996-06-07 1999-08-10 Procter & Gamble Dihidrobenzopirano e compostos a ele relacionados úteis como agentes antiflamatórios
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US6200990B1 (en) * 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
AU2458501A (en) 2000-01-05 2001-07-16 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
WO2002087547A1 (en) 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
ATE437637T1 (de) 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
HU227236B1 (en) 2002-11-06 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag New process for the production of racemic and the pure [2s[2r*[r[r*]]]]-and [2r[2s*[s[s*]]]]-enantiomers of nebivolol
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
BRPI0513672A (pt) * 2004-07-30 2008-05-13 Torrent Pharmaceuticals Limita processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
PL1776354T3 (pl) 2004-08-11 2010-09-30 Hetero Drugs Ltd Nowy sposób wytwarzania związków pośrednich nebiwololu
EP1850842A1 (de) 2005-02-11 2007-11-07 Stada Arzneimittel Ag Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer

Also Published As

Publication number Publication date
HRP20080297T3 (en) 2008-07-31
ZA200700765B (en) 2008-11-26
EP1741712A3 (de) 2007-04-04
RU2007106103A (ru) 2008-09-10
DE602005007339D1 (de) 2008-07-17
BRPI0513672A (pt) 2008-05-13
AU2005278782A1 (en) 2006-03-09
AU2005278782B2 (en) 2011-04-21
JP2015057407A (ja) 2015-03-26
US20130296583A1 (en) 2013-11-07
CN101006081B (zh) 2011-02-09
WO2006025070A3 (en) 2006-10-12
KR20070062507A (ko) 2007-06-15
WO2006025070A2 (en) 2006-03-09
ATE397605T1 (de) 2008-06-15
EP1741712B1 (de) 2011-06-15
CN101006081A (zh) 2007-07-25
EP1741712A2 (de) 2007-01-10
ES2307219T3 (es) 2008-11-16
KR100896266B1 (ko) 2009-05-08
US8633241B2 (en) 2014-01-21
JP5837975B2 (ja) 2015-12-24
JP2008508258A (ja) 2008-03-21
CN101862322A (zh) 2010-10-20
JP5757005B2 (ja) 2015-07-29
RU2378272C2 (ru) 2010-01-10
MX2007000911A (es) 2007-04-12
EP1737847A2 (de) 2007-01-03
US8604222B2 (en) 2013-12-10
JP2013151550A (ja) 2013-08-08
US20070259950A1 (en) 2007-11-08
EP1737847B1 (de) 2008-06-04
PL1737847T3 (pl) 2008-11-28

Similar Documents

Publication Publication Date Title
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
NO20083434L (no) Benzamid- og heteroarenderivater
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
NO20080033L (no) Kinolinderivater som NK3-antagonister
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
TW200800943A (en) Indane derivatives as MCH receptor antagonists
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
SE0401655D0 (sv) New compounds
SE0401763D0 (sv) Compounds
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
EA200701856A1 (ru) Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties